David Franklin joined MedAware as CEO to accelerate the company’s growth and to scale the company as it more aggressively enters the US market. He brings with him decades of entrepreneurial experience building and scaling health tech companies. He found his passion for early-stage growth companies as co-founder and COO of Connance, a healthcare predictive analytics company acquired by Waystar. Franklin also drove commercial success, enterprise profitability and business transformation in prior executive roles at Waystar, Finvi and Atlas Health. He splits his time in the US between Boston and La Jolla.

Gidi is a practicing physician, researcher and serial entrepreneur. Early in his career, Gidi served as CTO and Chief Architect of several algorithm-rich startup companies in Israel. In 2002, Gidi graduated from Tel Aviv University Medical School and later specialized in internal medicine, treating patients and teaching students and residents in one of Israel’s largest hospitals. Gidi received a PhD in Computational Biology from Tel Aviv University, harnessing mathematical and biological models to help fight breast cancer. In 2012 Gidi co-founded MedAware, utilizing machine learning algorithms to eliminate medication-related risks and promote patient safety.

Laly leads business development and strategic relationships for OurCrowd and its portfolio companies. Before joining OurCrowd, Laly held senior positions in business development and strategy across multiple industries in private and public companies. She also experienced the rollercoaster of being the CEO of a startup making eco-friendly cardboard products. Laly began her career as a lawyer and enjoyed six years in the upper west side of New York working at a leading firm on mergers & acquisitions and securities offerings. Laly served as a non-commissioned Education Officer in the IDF Officers School. She holds both a law degree (1997) and a Philosophy degree (1997, magna cum laudae) from Tel-Aviv University and an MBA from the Nash Honors Program at Baruch College (2000). Laly is a long distance runner and enjoys hiking with her family.

Tuvik has 15+ years of experience in the IT industry. He has served in roles of VP, chairman, and CEO and as an independent algorithmic consultant to organizations ranging from VC-backed startups to market-leading corporations. Tuvik brings to MedAware a unique combination of rich entrepreneurial experience, academic expertise in artificial intelligence, and hands-on experience in algorithmic development.

Eytan is a Professor of Computer Science and Medicine and a member of the Center for Bioinformatics and Computational Biology at the University of Maryland. His lab is an international leader in human metabolic modeling and he is an established authority in the areas of biomedical modeling and machine learning. He is a member of the editorial board of Artificial Intelligence in Medicine (AIM) and other journals on the interface of Computers and Medicine. Eytan has over 180 publications in leading scientific journals.

Allen is the co-founder and managing partner of Qure Ventures, Israel’s first exclusively focused digital health venture capital fund. A successful healthcare entrepreneur and corporate executive, Allen previously was a co-founder of Humedica, a transformative digital health company which was sold in 2013 to UnitedHealth (the largest U.S. health insurer). Following the acquisition, Allen served as the Chief Commercial Officer of Optum Analytics (a division in Optum, UnitedHealth Group’s health services company). With 25+ years of health care experience, Allen also was a director at leading healthcare investment bank, Leerink Swann (SVB Leerink), and held management positions at Biogen. He began his career reporting on FDA and policy issues for The Pink Sheet, and received his BA from Brandeis University.

Yoav is a private investor in technology and private equity ventures, with experience in both public and private sectors in various international markets.

Yuri is the Senior Director of Becton Dickinson’s Global Ambulatory Infusion business. In this role, he directs a globally dispersed and cross-functional team of almost 300 associates that continues to grow at a double-digit rate annually. Yuri has more than 15 years of cumulative experience in various business development and strategy roles in the Medical Device and IT industries. Yuri received his MBA from the University of Michigan and a BS degree in Medical Sciences from the Hebrew University of Jerusalem.

John D. Halamka is a Professor of Medicine at Harvard Medical School, President of the Mayo Clinic Platform, Co-chair of the National HIT Standards Committee, Co-chair of the Massachusetts HIT Advisory Committee, and a practicing Emergency Physician. As President of the Mayo Clinic Platform, he is responsible for elevating Mayo Clinic to a global leadership position within digital healthcare, leveraging emerging technologies such as artificial intelligence, connected healthcare devices, and natural language processing. Dr. Halamka has been developing and implementing healthcare information strategies and policies for more than 25 years and specializes in artificial intelligence, the adoption of electronic health records, and the secure sharing of healthcare data for care coordination, population health, and quality improvement. In 2020, Dr. Halamka was elected to the National Academy of Medicine (NAM).

Isaac Kohane co-directs the Center for Biomedical Informatics at Harvard Medical School where he applies computational techniques, whole genome analysis, and functional genomics to study human diseases. Kohane has led the use of whole healthcare systems, notably in the i2b2 project, as “living laboratories” to drive discovery research in disease genomics and pharmacovigilance and comparative effectiveness with software and methods adopted in over 84 academic health centers internationally. Dr. Kohane has published over 200 papers and leads a doctoral program in genomics and bioinformatics within the Division of Medical Science at Harvard University.

Michal Preminger is Head of Johnson & Johnson Innovation, East North America. Prior to this role, Michal served as the Executive Director of Harvard University’s Office of Technology Development (OTD), where she was responsible for development and commercialization of technologies emerging from research in laboratories and for the strategy and execution of all industry collaborations. Michal holds a PhD in Biological Sciences from the Weizmann Institute of Science, an MBA from INSEAD, Fontainebleau, France, and a BA in Medicine from the Hebrew University of Jerusalem.